Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC
November 3rd 2023
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.